FDA approves Sanofi's Infilbray as first treatment for neurological symptoms of type 3 Gaucher disease

Sanofi's oral glucosylceramide synthase inhibitor becomes the first FDA-approved medicine specifically targeting neurological symptoms of type 3 Gaucher disease, following evidence from a 52-week randomised study.
The US Food and Drug Administration approved Infilbray (venglustat) on 18 November 2026 for neurological symptoms of type 3 Gaucher disease in adults and children weighing at least 15 kg, introducing a treatment designed to address neurological manifestations of this rare inherited disorder.
The approval was supported by a 52-week randomised study involving 43 patients aged 12 years and older whose systemic disease had been stabilised with enzyme replacement therapy, with Infilbray demonstrating improvement on a combined neurological assessment; the medicine is not a cure and carries important psychiatric and reproductive safety considerations.
Field | Content |
Company | Sanofi |
Medicine | Infilbray (venglustat) |
Regulatory Authority | US Food and Drug Administration |
Approval Date | 18 November 2026 |
Approval Type | New medicine approval for neurological symptoms |
Therapeutic Area | Rare neurological and lysosomal storage diseases |
Indication | Neurological symptoms of type 3 Gaucher disease |
Eligible Population | Adults and children weighing at least 15 kg |
Drug Mechanism | Glucosylceramide synthase inhibition |
Administration | Oral |
Blood-Brain Barrier | Medicine crosses the blood-brain barrier |
Supporting Study | 52-week randomised study involving 43 patients aged 12 years and older with systemic disease stabilised on enzyme replacement therapy |
Efficacy Findings | Improvement on a combined neurological assessment compared with continued enzyme replacement therapy |
Existing Treatment Context | Enzyme replacement therapy addresses systemic manifestations but has limitations for neurological disease |
Safety Considerations | Psychiatric adverse effects and potential reproductive risks |
Regulatory Significance | First FDA-approved treatment specifically addressing neurological symptoms of type 3 Gaucher disease; not a cure |
Primary Source | https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-neurological-symptoms-type-3-gaucher-disease |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com



留言